Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $100 | $15,642 | $146 |
| Gross Profit | $0 | -$100 | -$15,642 | -$146 |
| % Margin | – | – | – | – |
| R&D Expenses | $20,860 | $15,187 | $15,642 | $8,787 |
| G&A Expenses | $0 | $3,965 | $4,133 | $0 |
| SG&A Expenses | $3,557 | $3,965 | $4,133 | $3,672 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$100 | -$15,642 | $0 |
| Operating Expenses | $24,417 | $19,052 | $4,133 | $12,459 |
| Operating Income | -$24,417 | -$19,152 | -$19,775 | -$12,605 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,075 | $1,490 | $2,797 | $3,075 |
| Pre-Tax Income | -$23,342 | -$17,662 | -$16,978 | -$9,530 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$23,342 | -$17,662 | -$16,978 | -$9,530 |
| % Margin | – | – | – | – |
| EPS | -1.9 | -1.44 | -1.39 | -0.78 |
| % Growth | -31.9% | -3.6% | -78.2% | – |
| EPS Diluted | -1.9 | -1.44 | -1.39 | -0.78 |
| Weighted Avg Shares Out | 12,307 | 12,240 | 12,202 | 12,179 |
| Weighted Avg Shares Out Dil | 12,307 | 12,240 | 12,202 | 12,179 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,125 | $1,314 | $1,681 | $3,554 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $100 | $81 | $146 |
| EBITDA | -$23,342 | -$17,562 | -$18,578 | -$9,384 |
| % Margin | – | – | – | – |